Loughborough, England, Oct. 04, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD), a medical know-how firm targeted on growing and commercializing a every day disposable, wearable glucose sensor and supporting personalised life-style teaching applications, proclaims at the moment that CEO Dr. Faz Chowdhury will current a company overview at at the MicroCap Rodeo Windy City Roundup 2022 Conference. The convention is being held on October 12 – 13, 2022 at the Swissotel Chicago.
Presentation Date: October 12, 2022
Time: 1:00 pm CT
Dr. Chowdhury can be out there for one-on-one conferences with traders who’re registered to attend the convention. To schedule a gathering, please e-mail [email protected]
To register for the convention, click on right here: https://microcaprodeo.com/signup
About Nemaura Medical, Inc.
Nemaura Medical, Inc. is a medical know-how firm growing and commercializing non-invasive wearable diagnostic units. The firm is at present commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark accepted Class IIb medical machine, is a non-invasive and versatile steady glucose monitor (CGM) offering actionable insights derived from actual time glucose measurements and every day glucose development information, which can assist individuals with diabetes and pre-diabetes to higher handle, reverse, and stop the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose information processed utilizing synthetic intelligence and a digital healthcare subscription service and has been launched in the U.S. as a basic wellness product as a part of its BEAT®diabetes program that’s at present present process pilot research.
Additionally, Nemaura has launched a beta trial of Miboko, a metabolic well being and well-being program utilizing a non-invasive glucose sensor together with an AI cellular software that helps a person perceive how sure meals and life-style habits can influence one’s total metabolic well being and well-being. Nemaura believes that up to half the inhabitants may benefit from a sensor and program that displays metabolic well being and well-being.
The Company sits at the intersection of the world Type 2 diabetes market that’s anticipated to attain almost $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight reduction and wellness functions that’s estimated to attain $60 billion by 2023.
For extra data, please go to www.NemauraMedical.com.
Contact:
Jules Abraham
CORE IR
917-885-7378
[email protected]
